Aspirin Use and Risk of Type 2 Diabetes in Apparently Healthy Men

American Journal of Medicine

Volumn 122, Issue 4, 2009, Pages 374-379

  Hayashino, Yasuaki ^a   Hennekens, Charles H ^b,c   Kurth, Tobias ^d,e  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aspirin; Cohort study; Diabetes; Epidemiology; Incidence; Men

Indexed keywords

ACETYLSALICYLIC ACID; BETA CAROTENE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG USE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PHYSICIAN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SELF REPORT; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RISK FACTORS;

EID: 63049084640     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.09.044     Document Type: Article

References (31)

1. Nilsson P.M., Roost M., Engstrom G., et al. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care 27 (2004) 2464-2469
2. Type 2 Diabetes Complications (2004). http://www.diabetes.org/type-2-diabetes/complications.jsp Accessed December 22, 2004.
3. Colwell J.A. Aspirin therapy in diabetes. Diabetes Care 27 Suppl 1 (2004) S72-S73
4. Ebstein W. Zur therapie des diabetes mellitus insbesondere uber die anwedung des salicylsauren natron bei demselben. Berl Klin Wochenschr 13 (1876) 337-340
5. Williamson R.T., and Loud M.D. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1 (1901) 760
6. Reid J., Macdougall A.I., and Andrews M.M. Aspirin and diabetes mellitus. Br Med J 2 (1957) 1071
7. Hundal R.S., Petersen K.F., Mayerson A.B., et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109 (2002) 1321-1326
8. Bratusch-Marrain P.R., Vierhapper H., Komjati M., and Waldhausl W.K. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia 28 (1985) 671-676
9. Giugliano D., Sacca L., Scognamiglio G., et al. Influence of acetylsalicylic acid on glucose turnover in normal man. Diabetes Metab 8 (1982) 279-282
10. Newman W.P., and Brodows R.G. Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab 57 (1983) 1102-1106
11. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
12. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321 (2000) 199-204
13. Pradhan A.D., and Ridker P.M. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur Heart J 23 (2002) 831-834
14. Helmersson J., Vessby B., Larsson A., and Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 109 (2004) 1729-1734
15. Yuan M., Konstantopoulos N., Lee J., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293 (2001) 1673-1677
16. Ismail N., Neyra R., and Hakim R. The medical and economical advantages of early referral of chronic renal failure patients to renal specialists. Nephrol Dial Transplant 13 (1998) 246-250
17. Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 318 (1988) 262-264
18. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 321 (1989) 129-135
19. Manson J.E., Buring J.E., Satterfield S., and Hennekens C.H. Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians. Am J Prev Med 7 (1991) 150-154
20. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334 (1996) 1145-1149
21. Sturmer T., Buring J.E., Lee I.M., et al. Colorectal cancer after start of nonsteroidal anti-inflammatory drug use. Am J Med 119 (2006) 494-502
22. Gilgore S.G. The influence of salicylate on hyperglycemia. Diabetes 9 (1960) 392
23. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
24. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
25. Maedler K., Sergeev P., Ris F., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110 (2002) 851-860
26. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
27. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
28. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
29. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 136 (2002) 157-160
30. Harris M.I. Prevalence of noninsulin-dependent diabetes and impaired glucose tolerance, in National Diabetes Data Group: Diabetes in America (1985), USDHHS, NIH Report No.: pub no 85-1468
31. Pradhan A.D., Cook N.R., Manson J.E., et al. A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 32 (2009) 3-8